RE: RE: RE: No brainer2 Dec 2016 12:30
SpikeyJ: as a practicing research scientist in the cancer arena I do think that the AZN oncology pipeline holds out some promise. However, it is a mixed bag and I think dear old Pascal oversold this very considerably while fending off Pfizer. I was dead against that merger as well, but for reasons other than the promise of AZN's drug development pipeline. Other moves are less favourable, such as the relocation of research activity from Cheshire to Cambridge, which could turn out to be very costly in more ways than one. I remain a holder, but have been so since sub £30 and the income I have earned over the years has been more than worth the hold alone.